Live from the NIH registry
Studies recruiting near Nashville right now
Top 25 of 1,347 recruiting studies, sorted by proximity — each links to its official registry page
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
B Acute Lymphoblastic Leukemia
Phase 2
Interventional 222 participants sought
The Children's Hospital at TriStar Centennial — Nashville, Tennessee (0.4 mi)
· Sponsor: National Cancer Institute (NCI)
ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Phase 1
Interventional 30 participants sought
Sarah Cannon Research Institute (SCRI) Oncology Partners — Nashville, Tennessee (0.4 mi)
· Sponsor: Acepodia Biotech, Inc.
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer
Phase 2
Interventional 120 participants sought
Sarah Cannon Research Institute (SCRI) Oncology Partners — Nashville, Tennessee (0.4 mi)
· Sponsor: Regeneron Pharmaceuticals
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
PIK3CA Mutation, HER2- Negative Breast Cancer
Phase 3
Interventional 540 participants sought
Tennessee Oncology, PLLC — Nashville, Tennessee (0.4 mi)
· Sponsor: Relay Therapeutics, Inc.
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
Neovascular Age-related Macular Degeneration
Phase 4
Interventional 188 participants sought
Tennessee Retina PC — Nashville, Tennessee (0.4 mi)
· Sponsor: Genentech, Inc.
Text-messaging Intervention to Support Parents After Their Child's Psychiatric Emergency
Parents, Self Efficacy
N/A
Interventional 90 participants sought
Vanderbilt University Medical Center — Nashville, Tennessee (0.4 mi)
· Sponsor: Vanderbilt University Medical Center
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
Chronic Migraine
Phase 3
Interventional 420 participants sought
Access Clinical Trials Inc /ID# 270280 — Nashville, Tennessee (0.4 mi)
· Sponsor: AbbVie
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
MTAP-deleted Solid Tumors
Phase 1, Phase 2
Interventional 450 participants sought
SCRI Oncology Partners — Nashville, Tennessee (0.4 mi)
· Sponsor: Bayer
GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab
Type 1 Diabetes
EARLY/Phase 1
Interventional 24 participants sought
Vanderbilt University Medical Center — Nashville, Tennessee (0.4 mi)
· Sponsor: Vanderbilt University Medical Center
BeSMART Secure Storage Counseling in the Inpatient Setting
Firearm Injury, Safety Issues
N/A
Interventional 400 participants sought
Monroe Carell Jr Children's Hospital at Vanderbilt — Nashville, Tennessee (0.4 mi)
· Sponsor: Vanderbilt University Medical Center
Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer
Advanced Breast Cancer
Phase 2
Interventional 24 participants sought
Research Site — Nashville, Tennessee (0.4 mi)
· Sponsor: AstraZeneca
Impact of Pelvic Pain Podcast
Chronic Pelvic Pain, Endometriosis
N/A
Interventional 100 participants sought
Vanderbilt Center for Women's Health — Nashville, Tennessee (0.4 mi)
· Sponsor: Vanderbilt University Medical Center
E-Mindfulness Approaches for Living After Breast Cancer
Breast Cancer, Depression
Phase 3
Interventional 402 participants sought
Vanderbilt Breast Center at One Hundred Oaks — Nashville, Tennessee (0.4 mi)
· Sponsor: NRG Oncology
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
Percutaneous Coronary Intervention, Peripheral Endovascular Intervention
Phase 4
Interventional 6,000 participants sought
TriStar Centennial Medical Center — Nashville, Tennessee (0.4 mi)
· Sponsor: Duke University
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms
Phase 3
Interventional 450 participants sought
Sarah Cannon Research Institute — Nashville, Tennessee (0.4 mi)
· Sponsor: Eli Lilly and Company
Stress and Opioid Misuse Risk: The Role of Endogenous Opioid and Endocannabinoid Mechanisms
Opioid Use Disorder, Back Pain
N/A
Interventional 120 participants sought
Vanderbilt University Medical Center — Nashville, Tennessee (0.4 mi)
· Sponsor: Vanderbilt University Medical Center
Comparing Healthcare Visit Recording and Open Notes to Improve Chronic iLlness Care Experience in Older Adults
Diabetes Mellitus, Hypertension
N/A
Interventional 1,022 participants sought
Vanderbit University Medical Center — Nashville, Tennessee (0.4 mi)
· Sponsor: Dartmouth-Hitchcock Medical Center
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer
Phase 3
Interventional 1,000 participants sought
Tennessee Oncology, PLLC - Investigational Drug Services — Nashville, Tennessee (0.4 mi)
· Sponsor: Pfizer
Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections
Pulmonary Invasive Fungal Infections, Pulmonary Invasive Aspergillosis
N/A
Observational 400 participants sought
Monroe Carell Jr. Children's Hospital at Vanderbilt — Nashville, Tennessee (0.4 mi)
· Sponsor: Arkansas Children's Hospital Research Institute
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Phase 1
Interventional 248 participants sought
Tennessee Oncology — Nashville, Tennessee (0.4 mi)
· Sponsor: Nurix Therapeutics, Inc.
The ArtixASCEND Study
Acute Lower Limb Arterial Occlusion
N/A
Interventional 250 participants sought
TriStar Centennial Medical Center — Nashville, Tennessee (0.4 mi)
· Sponsor: Inari Medical
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor
Phase 1
Interventional 104 participants sought
Research Facility — Nashville, Tennessee (0.4 mi)
· Sponsor: RayzeBio, Inc.
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Multiple Myeloma, Myeloma
Phase 1
Interventional 165 participants sought
Tennessee Oncology — Nashville, Tennessee (0.4 mi)
· Sponsor: K36 Therapeutics, Inc.
A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission
Acute HIV Infection
Phase 2
Interventional 48 participants sought
3652, Vanderbilt Therapeutics (VT) CRS — Nashville, Tennessee (0.4 mi)
· Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Sentence Shaping - DHH
Hearing Loss, Bilateral
N/A
Interventional 30 participants sought
Vanderbilt University Medical Center — Nashville, Tennessee (0.4 mi)
· Sponsor: Vanderbilt University